At the time of writing, Biomarin Pharmaceutical Inc. [BMRN] stock is trading at $86.87, up 7.95%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The BMRN shares have gain 2.94% over the last week, with a monthly amount glided 5.07%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Biomarin Pharmaceutical Inc. [NASDAQ: BMRN] stock has seen the most recent analyst activity on May 17, 2024, when Robert W. Baird downgraded its rating to a Neutral and also revised its price target to $72 from $104. Previously, Evercore ISI started tracking the stock with Outperform rating on May 14, 2024, and set its price target to $113. On November 15, 2023, Wells Fargo initiated with a Overweight rating and assigned a price target of $100 on the stock. Bernstein upgraded its rating to a Mkt Perform but stick to its price target of $82 on October 23, 2023. Raymond James initiated its recommendation with a Mkt Perform. UBS started tracking with a Buy rating for this stock on September 18, 2023, and assigned it a price target of $120. In a note dated July 27, 2023, Scotiabank initiated an Sector Perform rating and provided a target price of $95 on this stock.
For the past year, the stock price of Biomarin Pharmaceutical Inc. fluctuated between $73.68 and $99.56. Currently, Wall Street analysts expect the stock to reach $109.88 within the next 12 months. Biomarin Pharmaceutical Inc. [NASDAQ: BMRN] shares were valued at $86.87 at the most recent close of the market. An investor can expect a potential return of 26.49% based on the average BMRN price forecast.
Analyzing the BMRN fundamentals
According to Biomarin Pharmaceutical Inc. [NASDAQ:BMRN], the company’s sales were 2.59B for trailing twelve months, which represents an 19.18% jump. Gross Profit Margin for this corporation currently stands at 0.78% with Operating Profit Margin at 0.09%, Pretax Profit Margin comes in at 0.12%, and Net Profit Margin reading is 0.1%. To continue investigating profitability, this company’s Return on Assets is posted at 0.04, Equity is 0.05 and Total Capital is 0.04. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.21.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 84.32 points at the first support level, and at 81.77 for the second support level. However, for the 1st resistance point, the stock is sitting at 88.71, and for the 2nd resistance point, it is at 90.55.
Ratios To Look Out For
It is important to note that Biomarin Pharmaceutical Inc. [NASDAQ:BMRN] has a current ratio of 3.05. Also, the Quick Ratio is 1.95, while the Cash Ratio stands at 0.91. Considering the valuation of this stock, the price to sales ratio is 6.37, the price to book ratio is 3.13 and price to earnings (TTM) ratio is 65.58.
Transactions by insiders
Recent insider trading involved Mueller Brian, EVP, Chief Financial Officer, that happened on May 30 ’24 when 5000.0 shares were sold. EVP, Chief Legal Officer, Davis George Eric completed a deal on May 28 ’24 to sell 40850.0 shares. Meanwhile, Director BIENAIME JEAN JACQUES sold 20000.0 shares on May 10 ’24.
